The decision to forgo a U.S. registrational path in gastric cancer removes a near-term catalyst and shifts value to the ASPEN-09-Breast readout in mid-2027. Monitor for partnership announcements for the gastric cancer program and early data from ALX2004 Phase 1.
Price Chart
Executive Summary
ALX Oncology published Phase 2 ASPEN-06 data in Nature Medicine, showing evorpacept plus TRP achieved 40.3% ORR vs 26.6% control in HER2+ gastric cancer, with 63.6% ORR in high CD47/high HER2 subgroup. The company will not pursue a U.S. registrational Phase 3 in gastric cancer, instead seeking partnerships, and is focused on the ongoing Phase 2 ASPEN-09-Breast trial with mid-2027 topline data. The publication validates the biomarker strategy but the decision to forgo a registrational path in gastric cancer limits near-term upside.
Key Facts
- ASPEN-06 data published in Nature Medicine: evorpacept + TRP ORR 40.3% vs 26.6% control in ITT population
- In retained HER2-positive/high CD47 subgroup, ORR 63.6% vs 23.1% control; median PFS 19.5 vs 7.0 months; median DOR 25.5 vs 8.4 months
- ALX Oncology will not pursue a U.S. registrational Phase 3 in gastric cancer; will consider development partnerships for this program
- Ongoing Phase 2 ASPEN-09-Breast trial in HER2+ metastatic breast cancer on track for topline data from 80 patients in mid-2027
- Second pipeline candidate ALX2004 (EGFR-targeted ADC) in Phase 1 dose-escalation trial
Financial Impact
No financial data provided; company is clinical-stage with no approved products or revenue
Risk Factors
- No U.S. registrational path in gastric cancer limits commercial upside from ASPEN-06 data
- ASPEN-09-Breast topline data not expected until mid-2027, creating a long wait for next catalyst
- ALX2004 is early-stage (Phase 1) with no efficacy data disclosed
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3369826 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 9d ago | SC 13D/A | $1.14 $1.13 | ▼ −0.88% | ▼ −0.73% | $1.13 (−0.88%) |
Oct 15, 2026 11d ago | 8-K | $1.06 $1.17 | ▲ +10.38% | ▲ +10.81% | $1.13 (+6.60%) |
Sep 28, 2026 28d ago | Press Release | $1.39 $1.21 | ▼ −12.95% | ▼ −14.15% | $1.13 (−18.71%) |
Aug 15, 2026 10w ago | Institutional Cluster | $1.97 $1.99 | ▲ +1.02% | ▲ +2.21% | $1.13 (−42.64%) |
Aug 6, 2026 11w ago | 8-K | $2.11 $1.94 | ▼ −8.06% | ▼ −9.27% | $1.13 (−46.45%) |
Jun 30, 2026 16w ago | 8-K | $2.06 $2.36 | ▲ +14.56% | ▲ +14.30% | $1.13 (−45.15%) |
Jun 26, 2026 17w ago | 8-K | $2.20 $2.19 | ▼ −0.45% | ▼ −1.84% | $1.13 (−48.64%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.58 $1.53 | ▲ +3.16% | ▲ +3.84% | $1.13 (+28.48%) |
May 8, 2026 24w ago | 8-K | $2.08 $2.04 | ▼ −1.92% | ▼ −3.39% | $1.13 (−45.67%) |
May 8, 2026 24w ago | Press Release | $2.08 $2.04 | ▲ +1.92% | ▲ +3.39% | $1.13 (+45.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers